LeMaitre Vascular, Inc. (LMAT)
| Market Cap | 1.07B |
| Revenue (ttm) | 121.99M |
| Net Income (ttm) | 18.80M |
| Shares Out | 20.25M |
| EPS (ttm) | 1.04 |
| PE Ratio | 45.75 |
| Forward PE | 42.74 |
| Dividend | $0.38 |
| Dividend Yield | 0.80% |
| Trading Day | March 4 |
| Last Price | $47.59 |
| Previous Close | $50.78 |
| Change ($) | -3.20 |
| Change (%) | -6.29% |
| Day's Open | 50.41 |
| Day's Range | 46.30 - 50.74 |
| Day's Volume | 149,685 |
| 52-Week Range | 18.59 - 54.96 |
Shares of LeMaitre Vascular (NASDAQ:LMAT) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 47.83% over the past year to $...
BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2020 results and announced an $0.11/share ...
BURLINGTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in four upcoming investor conferences.
BURLINGTON, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2020 financial results on Thursday, February ...
BURLINGTON, Mass., Dec. 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in January.
The LeMaitre's corporate health partly depends on how much its sales reps can do to overcome current blocks, and how soon the pandemic ends.
LeMaitre has posted a strong quarter compounded by successful acquisition activity YTD, with little OPEX tied into profits in Q3. Management has widened the capital structure to be more debt i...
Here are five top-ranked liquid stocks, Winnebago Industries, (WGO), Shutterstock (SSTK), Logitech (LOGI), Ituran Location and Control (ITRN), and LeMaitre Vascular (LMAT), that investors can ...
Here are four top-ranked liquid stocks, Winnebago Industries (WGO), Shutterstock (SSTK), Logitech (LOGI), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen U.S. Small Company Growth Composite P...
BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at Jefferies Virtual London Healthcare Co...
BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in November.
LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2020 Results - Earnings Call Transcript
LeMaitre (LMAT) delivered earnings and revenue surprises of 76.19% and 13.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of LeMaitre Vascular (NASDAQ:LMAT) moved higher by 7.5% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 48.00% year over ye...
BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2020 results and announced ...
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BURLINGTON, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2020 financial results on Thursday, October 29...
To increase the likelihood of unearthing high-quality companies, Benjamin Graham, the pioneer of value investing, recommended screening the market for stocks with a current ratio of more than ...
To increase the likelihood of unearthing high-quality companies, Benjamin Graham, the pioneer of value investing, recommended screening the market for stocks with a current ratio of more than ...
LeMaitre Vascular is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2020 Results - Earnings Call Transcript
LeMaitre (LMAT) delivered earnings and revenue surprises of 440.00% and 59.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BURLINGTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2020 results and announce...
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BURLINGTON, Mass., July 10, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2020 financial results on Thursday, July 23...
BURLINGTON, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that it has acquired the business and assets of Artegraft, Inc. for $90.0 million, inclu...
MSA Safety, Fresnius Medical Care, and LeMaitre Vascular are well-priced stocks on the rise with solid dividends.
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q1 2020 Results - Earnings Call Transcript
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -2.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BURLINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, announced today Q1 2020 preliminary, unaud...
We take a look at three small and promising healthcare companies across diagnostics, surgical products, and genetic testing.
LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q4 2019 Results - Earnings Call Transcript
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -1.05%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Rising earnings move share prices up.
Looking for a shopping list of stocks to add to your portfolio? Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their top stock ideas for the year.
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs.
LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2019 Results - Earnings Call Transcript
LeMaitre (LMAT) delivered earnings and revenue surprises of 19.05% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BURLINGTON, Mass., Oct. 13, 2019 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), announced that it has acquired the biologic patch business of Admedus Ltd (ASX: AHZ) for $15.5 mi...
Chairman and CEO of Lemaitre Vascular Inc (30-Year Financial, Insider Trades) George W Lemaitre (insider trades) sold 66,037 shares of LMAT on 07/25/2019 at an average price of $34.45 a share.
LeMaitre Vascular Inc. (LMAT) CEO George LeMaitre on Q2 2019 Results - Earnings Call Transcript
LeMaitre (LMAT) delivered earnings and revenue surprises of 9.52% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
About LMAT
LeMaitre Vascular designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Oct 19, 2006 |
| CEO George LeMaitre | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol LMAT |
Financial Performance
In 2019, LMAT's revenue was $117.23 million, an increase of 11.05% compared to the previous year's $105.57 million. Earnings were $17.93 million, a decrease of -21.83%.
Analyst Forecasts
According to 5 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price forecast is 54.00, which is an increase of 13.48% from the latest price.